C12N 2770/20071
Demonstrated in vivo effect
C12N2770/20071 (Demonstrated in vivo effect) appears on 90 US grants and 260 published applications in this corpus.
Search patents in C12N- Granted patents
- 90
- Published applications
- 260
- Assignees
- 176
- Inventors
- 791
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 3 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 1 | 10 |
| 2017 | 2 | 6 |
| 2018 | 6 | 8 |
| 2019 | 8 | 5 |
| 2020 | 5 | 10 |
| 2021 | 8 | 19 |
| 2022 | 16 | 31 |
| 2023 | 8 | 72 |
| 2024 | 11 | 40 |
| 2025 | 16 | 40 |
| 2026 | 9 | 14 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- AAV5-based vaccine against SARS-CoV-215 Sep 2026US 12,734,235 B2
- Vaccines against viral pathogens7 Jul 2026US 12,673,096 B2Hexamer Therapeutics, Inc.
- Coronavirus vaccine23 Jun 2026US 12,661,394 B2Imperial College Innovations Limited
- SARS-CoV-2 polypeptides16 Jun 2026US 12,653,880 B2Mayo Foundation for Medical Education and Research
- SARS-CoV-2 vaccines and antibodies21 Apr 2026US 12,605,438 B2Rutgers, The State University of New Jersey
- Coronavirus vaccines and methods of use23 Jul 2026US 2026/0207734 A1BioNTech SE
- Variant strain-based coronavirus vaccines and uses thereof11 Jun 2026US 2026/0158135 A1ModernaTX, Inc.
- Method for constructing circular rna and vaccine against fipv21 May 2026US 2026/0137770 A1Beijing Syngentech Co., Ltd.
- Development of multi-antigen mrna vaccine against feline fipv21 May 2026US 2026/0137771 A1Beijing Syngentech Co., Ltd.
- Pan-sarbecovirus nanoparticle vaccines14 May 2026US 2026/0130986 A1University of Washington
Most cited
By later US patents
- Coronavirus vaccine51US 11,241,493 B2CureVac AG · 2022
- Antigen-binding molecule capable of binding two or more antigen molecules repeatedly33US 10,472,623 B2Chugai Seiyaku Kabushiki Kaisha · 2019
- Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly33US 9,890,377 B2Chugai Seiyaku Kabushiki Kaisha · 2018
- Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly28US 9,868,948 B2Chugai Seiyaku Kabushiki Kaisha · 2018
- Prefusion coronavirus spike proteins and their use25US 10,960,070 B2The Scripps Research Institute · 2021